10-Q: Dyadic International Reports Q1 2026 Results, Revenue Surges

Dyadic International's Q1 2026 report shows a significant 182.3% revenue increase driven by research and development, grant, and license/milestone revenues, alongside a narrowed net loss.

Summary

• Dyadic International reported a substantial 182.3% increase in total revenue for the first quarter of 2026, reaching $1.11 million compared to $393,572 in the same period of 2025.
• This revenue growth was primarily fueled by a $220,490 increase in research and development revenue from the Proliant Agreement, a $276,894 rise in grant revenue from CEPI and Gates Foundation initiatives, and a $200,000 milestone payment from the Inzymes Agreement.
• The cost of revenue also increased by 166.0% to $791,840, driven by higher costs associated with research and development and grant activities.
• Research and development expenses slightly decreased by 3.8% to $476,069, while general and administrative expenses rose by 10.0% to $1,755,331, attributed to increased legal, accounting, and rebranding costs.
• The company reported a net loss of $1,954,683 for Q1 2026, a slight improvement from the $2,027,579 net loss in Q1 2025, indicating a 3.6% reduction in net loss.
• As of March 31, 2026, Dyadic International held approximately $6.6 million in cash, cash equivalents, and investment securities, which management believes is sufficient for at least the next twelve months.
• The company is actively working to regain compliance with Nasdaq's minimum bid price rule and other listing standards, with potential actions including a reverse stock split.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with strong revenue growth and strategic progress offset by continued net losses and significant Nasdaq listing compliance risks.

Positives

• Total revenue increased significantly by 182.3% to $1.11 million in Q1 2026, driven by strong performance in R&D revenue, grant revenue, and license/milestone revenue.
• Net loss decreased by 3.6% to $1.95 million in Q1 2026, showing improved operational efficiency.
• The company has $6.6 million in cash, cash equivalents, and investment securities, providing a runway of at least 12 months.
• Commercial launch of AlbuFree DX recombinant human albumin by Proliant, produced using Dyadic's platform.
• Expansion of commercial efforts in Asia and Europe, and increased engagement with distribution partners.
• Successful completion of development activities and achievement of milestone payments under various collaboration agreements (e.g., Inzymes, Proliant).

Negatives

• The company continues to incur significant net losses, with a Q1 2026 net loss of $1.95 million.
• General and administrative expenses increased by 10.0% to $1.76 million.
• The company is not in compliance with Nasdaq's minimum bid price rule and other listing standards, facing potential delisting.
• Significant portion of revenue is concentrated among a few customers (86.3% in Q1 2026).
• Reliance on contract research organizations (CROs) for a substantial portion of research services (77.9% in Q1 2025, 63.4% in Q1 2026).

Risks

• Failure to comply with Nasdaq listing standards could lead to delisting, adversely affecting stock liquidity, market price, and the ability to raise capital.
• The company has a history of net losses and expects to continue incurring losses, raising substantial doubt about its ability to continue as a going concern.
• Market and regulatory acceptance of its protein production platforms and technologies.
• Failure to commercialize its platforms or other technologies.
• Competition from alternative technologies.
• Results of nonclinical studies and clinical trials.
• Capital needs and the ability to raise additional capital.
• Changes in global economic and financial conditions.
• Reliance on information technology and third parties.
• Government regulations and ESG issues.
• Intellectual property risks.
• The loss of business from one or a combination of its significant customers could adversely affect operations.
• The loss of one or a combination of its CROs could adversely affect operations.

Future Outlook

The company expects its existing cash, cash equivalents, restricted cash, and investment securities totaling approximately $6.6 million as of March 31, 2026, to be sufficient for at least the next twelve months. However, this estimate is based on assumptions that may prove incorrect, and the operating plan may change. If financing needs are not met, the company will seek additional capital through various means, which could be dilutive.

Management Comments

• The rebranding to Dyadic Applied BioSolutions marks a strategic transition from a research-driven organization to a commercially focused enterprise, better reflecting the emphasis on delivering applied biotechnology solutions.
• The company's focus is to commercialize high-value, non-therapeutic proteins, avoiding the regulatory complexity and high costs associated with therapeutic biologics.
• Management believes its existing cash and investments are sufficient for at least the next twelve months, but acknowledges the need for potential future capital raises.
• The company is actively pursuing strategies to regain compliance with Nasdaq listing standards, including potential shareholder approval for a reverse stock split.

Industry Context

StockSavvy.ai notes that Dyadic International's Q1 2026 results reflect a strategic pivot towards commercialization in the biotechnology sector, emphasizing non-therapeutic protein production. The significant revenue growth, driven by collaborations and grants, aligns with industry trends of leveraging specialized platforms like Dapibus and C1 for cost-effective protein development. However, the ongoing net losses and Nasdaq listing challenges are critical factors for investors to monitor.

Comparison to Industry Standards

• While specific comparable companies are not detailed in the filing, Dyadic's revenue growth of 182.3% in Q1 2026 is exceptionally high, suggesting strong traction in its niche markets. However, this growth is from a relatively small base.
• The company's focus on non-therapeutic proteins for life sciences, food, and bio-industrial markets positions it in a growing segment of the biotechnology industry, where demand for animal-free and cost-effective solutions is increasing.
• Many early-stage biotechnology companies experience similar patterns of high R&D spend, net losses, and reliance on external funding and collaborations, as seen with Dyadic's grant and licensing revenues.

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a materially adverse effect on its financial condition or results of operations.
• From time to time, the company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.

Related Party Transactions

• Convertible Notes were issued to immediate family members and family trusts related to Mark Emalfarb, the CEO.
• The Mark A. Emalfarb Trust purchased and was assigned $1,000,000 of Convertible Notes.
• The Francisco Trust, with Mr. Thomas Emalfarb (nephew of CEO) as trustee, holds Convertible Notes.
• Mr. Mark A. Emalfarb is the trustee of the Irrevocable Trust for his brother, Mr. Bradley S. Emalfarb.
• Messrs. Thomas Emalfarb, Scott Emalfarb, and Michael Emalfarb (nephews of CEO) are co-trustees of the Emalfarb Descendant Trust.
• Accrued interest on Convertible Notes for related parties totaled $41,800 as of March 31, 2026.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, risk of delisting from Nasdaq impacting stock value and liquidity, but also potential upside from successful commercialization and platform development.
• Employees: Continued employment and potential for stock-based compensation, but also risk associated with company's financial stability and Nasdaq listing.
• Collaborators/Partners: Continued collaboration on R&D and commercialization efforts, with potential for shared success and revenue.
• Creditors: Convertible notes are secured by a lien on substantially all assets, providing some security.

Next Steps

• Continue to advance the Dapibus and C1 protein production platforms.
• Commercialize high-value, non-therapeutic proteins in life sciences, food, nutrition, and industrial bioprocessing sectors.
• Pursue product development and sales and marketing activities with proceeds from the recent offering.
• Seek shareholder approval for a reverse stock split to address Nasdaq minimum bid price deficiency.
• Work to regain compliance with Nasdaq listing standards by the specified deadlines.
• Continue to expand commercial partnerships and distribution channels.
• Advance biopharmaceutical programs supported by grants from the Gates Foundation and CEPI.
• Broaden partner-led and internal development programs for non-animal dairy proteins and enzymes.

Key Dates

Recommendation

Dyadic International shows promising revenue growth and strategic advancements in its biotechnology platforms. However, the persistent net losses, significant cash burn, and critical Nasdaq listing compliance issues present substantial risks. While the company is actively seeking solutions, the uncertainty surrounding its ability to regain compliance and secure future funding warrants a cautious 'hold' recommendation until these risks are mitigated.

Keywords

Dyadic International, Form 10-Q, Biotechnology, Protein Production, Dapibus Platform, C1 Platform, Recombinant Proteins, Grant Revenue, License Revenue, Milestone Payments, Nasdaq Compliance, Financial Results, Q1 2026